Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.

You may also be interested in...

Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements

Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.

Arena Looking To Puff Up Belviq Sales With Smoking Indication

Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.

Qsymia, Belviq Make Progress With Aetna, But Coverage Remains Long-Term Challenge

Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts